Oncology News Central

Lung Cancer Rx

Health EN ↓ 14 episodios

LungCancerRx is a new podcast that features conversations among oncologists and patients. From tackling logistical obstacles to handling existential questions, these discussions aim to provide empowerment, knowledge, and hope across the lung cancer community. Eric K. Singhi, MD, a thoracic oncologist in Houston; Aakash Desai, MD, MPH, an assistant professor at the University of Alabama Birmingham’s O’Neal Cancer Center; and Fawzi Abu Rous, MD, a thoracic medical oncologist at Henry Ford Health in Detroit, cohost each episode. “We wanted to bridge the gap between provider communication and pati...

No dejes de visitar la web del podcast y apoyar a su creador: lungcancerrx.podbean.com

Autor

Oncology News Central

Categoría

Health

Web del podcast

lungcancerrx.podbean.com

Último episodio

31 de jul. de 2026

¿Dónde escuchar?

Podcasts en la app Replaio Radio Muy pronto

Los podcasts llegarán muy pronto a la app. Instálala ahora y sé el primero en descubrir una forma totalmente nueva de vivir los podcasts

Descárgala en Google Play Instálala gratis Android casi 10 M de descargas · valoración de 4,8 iOS muy pronto

Episodios

Why Lung Cancer Care Needs “Weed Killers” and “Crop Dusters” 31.07.2026

Aditya Juloori, MD, discusses the importance of demystifying the role of radiation oncology in lung cancer care with Aakash Desai, MD, MPH, and Fawzi F. Abu Rous, MD

More Accuracy, Less Speed? ASCO 2026 Data Further Support Targeted Therapy in Early-Stage NSCLC 26.06.2026

Data presented at ASCO 2026 further underscore the importance of identifying which patients with early-stage NSCLC are eligible for targeted therapies. Jamie E. Chaft, MD, discusses results from the LIBRETTO, CROWN, and EA5142 trials with LungCancerRx hosts Aakash Desai, MD, MPH, Eric K. Singhi, MD, and Fawzi F. Abu Rous, MD.

What Do ASCO 2026 Data on NSCLC Co-mutations Mean for Practice? 12.06.2026

Ferdinandos Skoulidis, MD, PhD, discusses data on KRAS- mutated NSCLC from ASCO 2026 with Aakash Desai, MD, MPH, Fawzi F. Abu Rous, MD, and Eric K. Singhi, MD.

Neoadjuvant Therapy for Early-Stage Lung Cancer: Where Do Things Stand, and What’s Next? 01.05.2026

Given recent advances, where do things stand for neoadjuvant therapy in patients with NSCLC? The panel discusses current considerations and what important questions may soon be answered. Patrick Forde MBBCh, PhD, a thoracic medical oncologist at Johns Hopkins University in Baltimore, Maryland, and professor of immuno-oncology at Trinity College Dublin discusses current multidisciplinary approaches...

Lung Cancer Myths: Separating Fact From Fiction 13.03.2026

From screening to treatment, myths and misperceptions about lung cancer present challenges for physicians and patients. From setting the record straight on surgical approaches to setting higher expectations for treatment outcomes, the LungCancerRx panel tackles key questions currently faced in practice.

“Just Doesn’t Make Sense”: What’s Missing When It Comes to Diagnosing Lung Cancer 27.02.2026

Despite notable recent advances in lung cancer treatment, early diagnosis remains a challenge. From problems with screening criteria to changes in disease demographics, the LungCancerRx panel explains why the only solution is “education, education, education.”

“We Want to Stop the Gatekeeping of Information”: The Origin of LungCancerRx 05.12.2025

To cap off the first year of the LungCancerRx podcast, cohosts Aakash Desai, MD, MPH; Eric K. Singhi, MD; and Fawzi F. Abu Rous, MD, share how they first came together and what they see as their mission for the series moving forward. “I think we want to stop the gatekeeping of information,” Dr. Singhi explained.

“Absolute Flood” of ADCs and Key Data Lead to “Good Challenges” in EGFR-Mutated NSCLC 21.11.2025

In this episode of LungCancerRx, Eric Singhi, MD, Aakash Desai, MD, MPH, and Fawzi F. Abu Rous, MD, welcome Julia Rotow, MD to the conversation. “I think we’ve been very lucky, in the world of EGFR-mutated lung cancer, that it has gotten so complicated,” explains  Julia Rotow, MD , clinical director of the Lowe Center for Thoracic Oncology and director of clinical research at the Dana-Farber Cance...

“It Unlocks This Whole World”: Better Understanding of Lung Cancer Is Generating Better Outcomes 26.09.2025

In this episode of LungCancerRx, the experts talk about key trials presented at the World Conference on Lung Cancer, and the rapidly shifting landscape in lung cancer treatment, which now can be treated as multiple different diseases. Cohost Eric Singhi, MD, is joined by Bruna Pellini, MD, Antonio Calles, MD, and Stephen Liu, MD.

“Milestone” in EGFR-Positive NSCLC: The Importance of Options for Patient-Centered Care 12.09.2025

In this episode of LungCancerRx, the experts talk about the FLAURA2 and HARMONi data presented at the World Conference on Lung Cancer and what the findings mean for patients with EGFR-mutated non-small cell lung cancer (NSCLC). Recorded onsite in Barcelona, Spain, cohost Eric Singhi, MD, from Houston, Texas, is joined by Bruna Pellini, MD, from Moffitt Cancer Center and Research Institute in Tampa...

“What I Tell My Patients”: Making Sense of New Treatment Options in EGFR-positive NSCLC 22.08.2025

In this episode of LungCancerRx, Eric Singhi, MD, Aakash Desai, MD, MPH, and Fawzi F. Abu Rous, MD, welcome back Christine M. Lovly, MD, PhD, to talk about the complexities of treating advanced EGFR-positive NSCLC. Dr. Lovely shares how she talks with patients about the latest data and recent trials.

Say No to Jargon, Yes to Testing: Oncologists Face Tough Patient Conversations in NSCLC 08.08.2025

As oncologists stand on “the cutting edge” of neoadjuvant treatment for EGFR-mutated lung cancer, how should they conduct complex conversations with patients? Christine M. Lovly, MD, PhD, joins hosts Aakash Desai, MD, MPH; Eric K. Singhi, MD; and Fawzi F. Abu Rous, MD, for an honest discussion about current challenges.

Empowered Choices: “The Most Important Conversations” Oncologists Can Have With NSCLC Patients 11.07.2025

When it comes to treatment decisions for patients with EGFR-mutated non-small cell lung cancer, “the most important conversations are not the data-driven ones, they are the relational ones,” says patient advocate  Jill Feldman . In the second episode of the LungCancerRx video podcast, cohosts  Fawzi F. Abu Rous, MD , a thoracic medical oncologist at Henry Ford Health in Detroit; Eric K. Singhi, MD...

Empowered Voices: The Journey to Patient Advocacy 12.06.2025

In the first episode of the LungCancerRx video podcast, cohosts Eric K. Singhi, MD, a thoracic oncologist in Houston;  Aakash Desai, MD, MPH , an assistant professor at the University of Alabama at Birmingham’s O'Neal Cancer Center; and  Fawzi Abu Rous, MD , a thoracic medical oncologist at Henry Ford Health in Detroit; are joined by patient advocate  Jill Feldman . They talk about her experience...

Escucha el podcast Lung Cancer Rx en Replaio

Radio y podcasts en una sola app - gratis y sin registro. Instálala hoy y no te pierdas el estreno

Descárgala en Google Play

Replaio no es editor de podcasts; los nombres de los programas, las portadas y el audio pertenecen a sus autores y se distribuyen a través de canales RSS públicos